Psicofármacos e alterações metabólicas

Autores

DOI:

https://doi.org/10.25118/2763-9037.2023.v13.439

Palavras-chave:

substâncias psicotrópicas, efeitos colaterais e reações adversas relacionadas a drogas, efeitos colaterais metabólicos de drogas e substâncias

Resumo

Objetivo: O objetivo deste artigo é promover uma revisão da literatura e uma visão geral das evidências dos impactos metabólicos do uso de drogas psicotrópicas sobre as alterações metabólicas. Métodos: Uma revisão descritiva, incluindo artigos em inglês e português, foi realizada nas bases de dados do Google Scholar e PubMed, usando as seguintes palavras-chaves:  peso corporal, dislipidemia, síndrome metabólica e antipsicóticos, estabilizadores do humor e antidepressivos no PubMed, e dislipidemia, peso corporal, síndrome metabólica associada a antipsicóticos, estabilizadores do humor e antidepressivos no Google Scholar. Resultados: Foram analisados 46 artigos e 46 artigos foram incluídos. A revisão revelou uma grande quantidade de evidências relativas às mudanças de peso corporal sob uso de drogas psicotrópicas e o impacto dos antipsicóticos sobre as principais variáveis metabólicas. Entretanto, foram notadas controvérsias e escassas evidências sobre estabilizadores de humor em alterações glicêmicas e dislipidêmicas, e especialmente sobre antidepressivos em alterações metabólicas. Conclusões: Conclui-se que o impacto das drogas psicotrópicas nas alterações metabólicas tem grande relevância clínica e é caracterizado como um desafio para a psicofarmacologia moderna. Tais alterações, vistas como possíveis efeitos colaterais de tais drogas, afetam diretamente a qualidade e a expectativa de vida do paciente, portanto, merecendo atenção para obtenção de sucesso no tratamento psiquiátrico e no contexto holístico de saúde.

 

 

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Biografia do Autor

Tainá Patrícia Teixeira Bezerra, Discente, Universidade Federal da Paraíba, UFPB, João Pessoa, Brasil

Alba Inêz Celestino Rezende Fabrício, Universidade Federal da Paraíba, UFPB, João Pessoa, Brasil

Alfredo José Minervino, Psiquiatra, Universidade Federal da Paraíba, UFPB, João Pessoa, Brasil

Roberto Mendes dos Santos, Psiquiatra, Universidade Federal da Paraíba, UFPB, João Pessoa, Brasil

Referências

Gorenstein C, Scavone C. Avanços em psicofarmacologia: mecanismos de ação de psicofármacos hoje. Rev Bras Psiquiatr. 1999;21(1):64-73. https://doi.org/10.1590/S1516-44461999000100012

Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124(7):978-82. https://doi.org/10.1176/ajp.124.7.978 - PMid:5634402

Pedrero LA, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. 2019:1-11. https://doi.org/10.1111/obr.12934 - PMid:31524318

Malhi GS, Mitchell PB, Caterson I. "Why getting fat, Doc?" Weight gain and psychotropic medications. Aust N Z J Psychiatry. 2001;35(3):315-21. https://doi.org/10.1046/j.1440-1614.2001.00891.x - PMid:11437804

Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8(5):323-330. https://doi.org/10.1097/00004714-198810000-00003 PMid:3053797

Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl)1:37-41. https://doi.org/10.4088/JCP.v61n1109 PMid:11105740

Schneider M, Pauwels P, Toto S, Bleich S, Grohmann R, Heinze M, Greiner T. Severe weight gain as an adverse drug reaction of psychotropics: data from the AMSP project between 2001 and 2016. Eur Neuropsychopharmacol. 2020;36:60-71. https://doi.org/10.1016/j.euroneuro.2020.05.001 - PMid:32536570

Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-43. https://doi.org/10.1192/bjp.187.6.537 - PMid:16319406

Sachs G, Bowden C, Calabrese JR, Ketter T, Thompson T, White R, Bentley B. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006;8(2):175-81. https://doi.org/10.1111/j.1399-5618.2006.00308.x - PMid:16542188

Bond DJ, Kunz M, Torres IJ, Lam RW, Yatham LN. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord. 2010;12(6):616-26. https://doi.org/10.1111/j.1399-5618.2010.00855.x PMid:20868460

Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. 2018;36(1). https://doi.org/10.1515/hmbci-2017-0065 PMid:29320364 - PMCid:PMC6818518

Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193-220. https://doi.org/10.1016/S0022-3956(03)00018-9 - PMid:12650740

Holt RIG, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med. 2004;21(6):515-23. https://doi.org/10.1111/j.1464-5491.2004.01199.x PMid:15154933

Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl. 18):13-26. https://www.psychiatrist.com/read-pdf/18975/

McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol. 2003;23(4):323-7. https://doi.org/10.1097/01.jcp.0000085403.08426.f4 PMid:12920406

Teixeira PJR, Rocha FL. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor. Rev Psiquiatr do Rio Gd do Sul. 2006;28(2):186-96. https://doi.org/10.1590/S0101-81082006000200011

Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry. 2004;65(10):1335-42. https://doi.org/10.4088/JCP.v65n1007 - PMid:15491236

Littrell KH, Petty RG, Hilligoss NM, Kirshner C, Johnson CG. The effect of aripiprazole on insulin resistance in schizophrenia. In: Proceedings of the 157th Annual Meeting of the American Psychiatric Association. New York: APA; 2004.

Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology. 1987;17(3):130-2. https://doi.org/10.1159/000118351 - PMid:3683801

McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, Baker RA. A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord. 2011;13(6). https://doi.org/10.4088/PCC.11m01182

Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obejity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006;67(12):1974-82. https://doi.org/10.4088/JCP.v67n1219 PMid:17194277

Ijaz S, Bolea B, Davies S, Savović J, Richards A, Sullivan S, Moran P. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18(1):275. https://doi.org/10.1176/appi.focus.18307 PMid:33343261 - PMCid:PMC7725149

Monteleone P, Martiadis V, Maj M. Management of Schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am. 2009;32(4):775-94. https://dx.doi.org/10.1016/j.psc.2009.08.003 - PMid:19944883

Galling B, Roldán A, Rietschel L, Hagi K, Walyzada F, Zheng W, Cao X-L, Xiang Y-T, Kane JM, Correll CU. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016;15(5):591-612. https://doi.org/10.1517/14740338.2016.1165668 - PMid:26967126

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-403. https://doi.org/10.1093/schbul/sbu030 PMid:24636967 PMCid:PMC4193713

Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923(1-2):82-90. https://doi.org/10.1016/S0006-8993(01)03026-8 - PMid:11743975

Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-42. https://doi.org/10.1517/14740338.2012.683523 PMid:22563628 PMCid:PMC3384511

Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res. 2015;62:38-47. https://doi.org/10.1016/j.jpsychires.2015.01.004 - PMid:25619176

Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I. The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology. 1983;33(4):510. https://doi.org/10.1212/WNL.33.4.510 - PMid:6403892

Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, Manfredi R, Hsin-Nanh L. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol. 2010;25(2):60-7. https://doi.org/10.1097/YIC.0b013e328333ac1b - PMid:20101186

Carman CL, Leung NM, Gnberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;24(3):240-4. https://doi.org/10.1017/S0317167100021879 - PMid:9276111

Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5):e32-e43. https://doi.org/10.1111/j.1467-789X.2010.00800.x PMid:20880119

Franzoni E, Govoni M, D'Addato S, Gualandi S, Sangiorgi Z, Descovich GC, Salvioli GP. Total cholesterol, high‐density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia. 1992;33(5):932-5. https://doi.org/10.1111/j.1528-1157.1992.tb02203.x PMid:1396438

Mahmoudi-Gharaei J, Shahrivar Z, Faghihi T, Mohammadi MR, Tehrani-Doost M, Alaghband-Rad J, Ghaeli P. Topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar I disorder: effects on weight and serum lipid profiles. Iran J Psychiatry. 2012;7(1):1-10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395968/

Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram. In: 37th annual meeting of the American College of Neuropsychopharmacology. 1998.

Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-72. https://doi.org/10.4088/JCP.09r05346blu PMid:21062615

Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley Jr CM. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8):1170-6. https://doi.org/10.1176/ajp.156.8.1170 - PMid:10450256

Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64(Suppl 8):22-9. - PMID:12892538

Li H, Fang M, Xu M, Li S, Du J, Li W, Chen H. Chronic olanzapine treatment induces disorders of plasma fatty acid profile in Balb/c Mice: a potential mechanism for olanzapine-induced insulin resistance. PLoS One. 2016;11(12):e0167930. https://doi.org/10.1371/journal.pone.0167930 PMid:27973621 - PMCid:PMC5156395

Eker ÖO, Özsoy S, Eker B, Doğan H. Metabolic effects of antidepressant treatment. 2017;(10):49-56. https://doi.org/10.5152/npa.2016.12373 - PMid:28566959 - PMCid:PMC5439472

Gramaglia C, Gambaro E, Bartolomei G, Camera P, Chiarelli-serra M, Lorenzini L, Zeppegno P. Increased risk of metabolic syndrome in antidepressants users: a mini review. Front. Psychiatry. Sec. Psychological Therapy and Psychosomatics. 2018;9. https://doi.org/10.3389/fpsyt.2018.00621 PMid:30546325 - PMCid:PMC6279880

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. 1999;156(11):1686-1696. https://doi.org/10.1176/ajp.156.11.1686 - PMid:10553730

CORDÁS TA, KACHANI AT. Nutrição em Psiquiatria. Barueri: MNOLE; 2005. 415 p.

Second-generation NJ. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl. 1):1-93. https://doi.org/10.2165/00023210-200519001-00001 - PMid:15998156

Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, Pickar D, Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacol. 1999;20(1):29-34. https://doi.org/10.1016/S0893-133X(98)00047-5 PMid:9885782

Correll CU, Agarwal V, De Hert M, Manu P P, Cohen D, Nielsen J. Selective effects of individual antipsychotic cotreatments on cardiometabolic and hormonal risk status: results from a systematic review and meta-analysis. Schizophrenia Bulletin. U.S. Dept. of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration; 2013. lirias1768552. https://kuleuven.limo.libis.be/discovery/fulldisplay?docid=lirias1768552&context=SearchWebhook&vid=32KUL_KUL:Lirias&lang=en&search_scope=lirias_profile&adaptor=SearchWebhook&tab=LIRIAS&query=any,contains,lirias1768552&offset=0

Downloads

Publicado

2023-01-14

Como Citar

1.
Teixeira Bezerra TP, Fabrício AICR, Minervino AJ, Santos RM dos. Psicofármacos e alterações metabólicas . Debates em Psiquiatria [Internet]. 14º de janeiro de 2023 [citado 1º de fevereiro de 2023];13:1-20. Disponível em: https://revistardp.org.br/revista/article/view/439

Edição

Seção

Artigos de Revisão

Plaudit

Métricas